Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jing-Jin Che"'
Autor:
Wen-Bo Dai, Jia-Yi Ren, Su-Tao Hu, Yu-Kun Zhang, Tian-Shu Gu, Xue Wu, Jing-Kun Zhang, Jing-Jin Che, Xiang-Hong Ma, Tong Liu, Guang-Ping Li, Kang-Yin Chen
Publikováno v:
Platelets, Vol 35, Iss 1 (2024)
Currently, the standard treatment for patients who have undergone percutaneous coronary intervention (PCI) following acute myocardial infarction (MI) involves dual antiplatelet therapy (DAPT) with a combination of aspirin and a potent P2Y12 receptor
Externí odkaz:
https://doaj.org/article/9df3cb9938d244b59235528f3352b48e
Autor:
Hao Zhang, Shao-Hua Guo, Zheng-Kai Xue, Ya-Ru Zhang, Jia-Rui Wang, Jing-Jin Che, Tong Liu, Hua-Yue Tao, Guang-Ping Li, Seung-Woon Rha, Swapnil-Zaman Ashraful-Haque, Kang-Yin Chen
Publikováno v:
Clinics, Vol 76 (2021)
OBJECTIVES: This study assessed the protective effect of calcium dobesilate against contrast-induced nephropathy (CIN) after coronary angiography (CAG) or percutaneous coronary intervention (PCI) in patients with diabetes and chronic kidney disease (
Externí odkaz:
https://doaj.org/article/7384f1561b6147b688c05e406a5f1261
Autor:
Tong Liu, Peng Wang, Zheng Kai Xue, Ling Xia Xu, Jia Rui Wang, Xuewen Wang, Seung-Woon Rha, Wei Ding Wang, Jing Jin Che, Ya Ru Zhang, Kang Yin Chen, Hua Yue Tao
Publikováno v:
Perfusion. 36(2)
Background: Periprocedural myocardial infarction is a common complication following percutaneous coronary intervention. The present study was conducted with an aim to compare the safety and efficacy of loading doses of ticagrelor versus clopidogrel i
Autor:
Shuai Miao, Zheng-Kai Xue, Ya-Ru Zhang, Hao Zhang, Jing-Jin Che, Tong Liu, Hua-Yue Tao, Guangping Li, Kang-Yin Chen
Publikováno v:
Medical Science Monitor; 4/30/2021, Vol. 27, p1-7, 7p
Autor:
Xin Tian Zheng, Seung-Woon Rha, Ling Xia Xu, Kang Yin Chen, Guang Ping Li, Jing Jin Che, Tong Liu
Publikováno v:
Clinical and experimental pharmacologyphysiology. 43(1)
Patients with complex coronary lesions undergoing percutaneous coronary intervention (PCI) have more major adverse cardiac events (MACE) than do those with simpler cases. Therefore, intensive antiplatelet therapy might be needed in these patients. A